Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Immunoassays for everolimus

Inactive Publication Date: 2005-09-22
SERADYN INC
View PDF7 Cites 13 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0007] The present invention is directed to novel derivatives of everolimus and novel everolimus immunogens. The present invention is also directed to polyclonal and monoclonal antibodies generate

Problems solved by technology

The complexity of the clinical state, individual differences in sensitivity to immunosuppressive and nephrotoxic effects, has been rather challenging for physicians to balance between therapeutic efficacy and the occurrence of side effects (Wallemac

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Immunoassays for everolimus
  • Immunoassays for everolimus
  • Immunoassays for everolimus

Examples

Experimental program
Comparison scheme
Effect test

example 1

Synthesis of Immunogenic Compounds and Labeled Competitors Synthesis of RAD-mono-formate

[0077] 0.6 g of RAD was dissolved in 2 mL of dry methylene chloride in a 100 mL round bottom flask under an atmosphere of argon (Ar). An aliquot (˜10 μL) was saved for HPLC and TLC assays. The round bottom flask containing the reaction solution was placed in the ice / NaCl bath at about −20° C. The reaction flask was allowed to cool down for 3-5 min. Dry pyridine (0.25 mL) was added using a dry glass syringe with a metal needle (15 cm) all at once. 0.35 mL dry allyl chloroformate was added using a dry glass syringe with a metal needle (15 cm) within about ½-1 min. Shortly after addition, precipitation occurred. The stirring was allowed for one hour. The reaction was quenched by adding 5 mL of saturated NaHCO3. The quenched reaction was extracted with methylene chloride. The organic phase was combined, dried (Na2SO4) and filtered. The filtrate was transferred to a 250 ml bottom flask (100-250 mL) a...

example ii

Antibody Preparation

[0089] Polyclonal anti-everolimus antibodies can be prepared by conventional methods. Animals were immunized with everolimus immunogen (RAD 822 / BSA), as produced in Example I. The immunization program started with initial injection of 0.5 ml immunogen mixing with 0.5 complete Freunds adjuvant. Subsequent injections were performed with 0.5 ml immunogen mixing with 0.5 incomplete Freunds adjuvant. Animals were typically injected every two weeks. Sera were screened via FPIA using RAD 822: FAMCO-E tracer. Several bi-monthly production bleeds (˜20 mL per bleed) from three rabbits were pooled together. Before filter and dilution, the total pooled volume is about 500 mL. Anti-Sera from Rabbit were filtered with 0.2 um Cellulose Acetate Filter under vacuum and diluted with phosphate buffer with sodium azide and sodium chloride at pH 7.5. The final volume is about 1000 ml.

[0090] Monoclonal anti-everolimus antibodies can be prepared by immunization of mice. A mouse can b...

example iii

Fluorescence Polarization Immunoassay using RAD 822: FAMCO-E tracer Automated Fluorescence Polarization Immunoassay (FPIA)

[0091] This example describes an exemplary fluorescence polarization immunoassay (FPIA) for everolimus.

[0092] The fluorescence polarization immunoassay was performed using an automated TDx polarization analyzer (Abbott Laboratories, Irving, Tex.) using a competitive assay included anti-analyte antibody (the anti-everolimus antibody of Example II) or “A”, a fluorescein:everolimus analog conjugate (tracer or “T”), and a pretreatment buffer or “B.” The calibration of the automated assay described in the examples was achieved with a series of six calibrators that include specified concentrations of everolimus spiked into human serum. Patient samples (plasma) are placed in plastic sample cups in a circular carousel designed for the TDx instrument. The automated assay is described in detail in literature available from Abbott Laboratories, Irving, Tex. It is understo...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
Fractionaaaaaaaaaa
Concentrationaaaaaaaaaa
Concentrationaaaaaaaaaa
Login to View More

Abstract

Immunoassays for the detection of everolimus are provided. Compounds for producing antibodies for everolimus, as well as antibodies produced therefrom, are also provided.

Description

[0001] This application claims priority to U.S. Provisional Application No. 60 / 551,989, filed Mar. 10, 2004, herein incorporated by reference.FIELD OF INVENTION [0002] The invention relates generally to reagents and methods for determination of everolimus in biological fluids. BACKGROUND OF THE INVENTION [0003] The everolimus [40-O-(2-hydroxyethyl)-rapamycin] is a novel macrolide immunosuppressant. Everolimus (also known as SDZ-RAD, RAD, Certican®) was developed by Novartis (Nashan B. The role of Certican in the many pathways of chronic rejection. Transplantation Proceedings, 2001, 33: 3215-3230, herein incorporated by reference) in an effort to improve upon rapamycin (Sirolimus), a proliferation signal inhibitor that blocks growth factor-driven transduction signals in the cellular responses to alloantigen (Cottens S, et al. O-Alkylated rapamycin derivatives and their use, particularly as immunosupressants. WO-009409010 28-April-94, herein incorporated by reference). Everolimus has ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/385C07D267/22C07K16/44C07K17/00G01N33/53G01N33/531G01N33/532G01N33/533G01N33/537G01N33/543G01N33/94
CPCC07K16/44G01N33/9466G01N33/9493Y10T436/13Y10S435/975Y10S436/815Y10S530/807Y10S435/81
Inventor ROBERTS, MARKARABSHAHI, LILIBOYD, JAREDDENNIS, CHRISTOPHER T.MARBACH, PETERAARON, GEORGEHWANG, DENGSHVETS, ALEXEI BORIS
Owner SERADYN INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com